Zobrazeno 1 - 10
of 700
pro vyhledávání: '"Joseph A. DiMasi"'
Autor:
Joseph A. DiMasi, Abigail Dirks, Zachary Smith, Sarah Valentine, Jennifer C. Goldsack, Thomas Metcalfe, Upinder Grewal, Lada Leyens, Ute Conradi, Daniel Karlin, Lesley Maloney, Kenneth A. Getz, Bert Hartog
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 8, Pp n/a-n/a (2024)
Abstract In the last few decades, developers of new drugs, biologics, and devices have increasingly leveraged digital health technologies (DHTs) to assess clinical trial digital endpoints. To our knowledge, a comprehensive assessment of the financial
Externí odkaz:
https://doaj.org/article/77fe2a1b251a485ba326668889f4aa2c
Publikováno v:
Research Technology Management, 2003 Sep 01. 46(5), 64-64.
Externí odkaz:
https://www.jstor.org/stable/43240141
Autor:
Joseph A. DiMasi, Zachary Smith, Ingrid Oakley-Girvan, Andrew Mackinnon, Mary Costello, Pamela Tenaerts, Kenneth A. Getz
Publikováno v:
Therapeutic Innovation & Regulatory Science. 57:209-219
Background Deployment of remote and virtual clinical trial methods and technologies, referred to collectively as decentralized clinical trials (DCTs), represents a profound shift in clinical trial practice. To our knowledge, a comprehensive assessmen
Publikováno v:
Nature Reviews Drug Discovery. 22:344-345
Autor:
Michael Wilkinson, Joseph A. DiMasi
Publikováno v:
Therapeutic Innovation & Regulatory Science. 54:1453-1460
Faster drug development times get new therapies to patients sooner and financially benefit drug developers by shortening the time between investment and returns and increasing the time on the market with intellectual property protection. The result i
Autor:
Yaritza Peña, Stella Stergiopoulos, Zachary Smith, Michael Wilkinson, Kenneth A. Getz, Maria I. Florez, Joseph A. DiMasi
Publikováno v:
Clinical Pharmacology & Therapeutics. 107:324-332
We gathered data from three pipeline databases and other public sources on development stage and clinical trial metrics for 1,914 investigational drugs, biologics, and vaccines and 2,769 clinical trials intended to treat a wide variety of infectious
Autor:
Thomas L. Holland, Josephine Awatin, Stella Stergiopoulos, Joseph A. DiMasi, Carrie A. Brown, Kenneth A. Getz, Sara B. Calvert, Pamela Tenaerts
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
A hospital-acquired and ventilator-associated bacterial pneumonia phase 3 clinical trial cost model estimates costs at $89600 per patient. The biggest cost driver is screen failure rates. Strategies to decrease screen failures are needed to improve t
Autor:
Eeshan Khandekar, John A. Wagner, Lynn D. Hudson, Joseph A. DiMasi, Steven K. Galson, Christopher P. Austin, Robert M. Califf
Publikováno v:
Nature Reviews Drug Discovery. 20:259-260
Publikováno v:
Therapeutic Innovation & Regulatory Science. 50:759-768
With available funding from the public sector decreasing while medical needs and scientific complexity increase, private-sector collaborations with academia and government have become increasingly key in furthering medical innovation. Nonetheless, so
Autor:
Joseph A. DiMasi, Ranjana Chakravarthy
Publikováno v:
Clinical Pharmacology & Therapeutics. 100:754-760
We examined data on the entry rates of second and later entrants in 43 pharmacologic classes, as well as the timing of patent filings and development milestones for 79 later-in-class drugs. The median time to when a second entrant was approved was 2.